The latest price target for Immutep (NASDAQ:IMMP) was reported by Citizens on March 13, 2026. The analyst firm set a price target for $0.00 expecting IMMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Immutep (NASDAQ:IMMP) was provided by Citizens, and Immutep downgraded their market perform rating.

There is no last upgrade for Immutep

The last downgrade for Immutep Ltd happened on March 13, 2026 when Citizens changed their price target from N/A to N/A for Immutep Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immutep, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immutep was filed on March 13, 2026 so you should expect the next rating to be made available sometime around March 13, 2027.

While ratings are subjective and will change, the latest Immutep (IMMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Immutep (IMMP) is trading at is $0.41, which is out of the analyst’s predicted range.